Científico en la computadora

Publicaciones científicas

7.9 billon people are still living through COVID-19 it is not over.

Up to 50% of people infected with COVID-19 don´t show symptoms.

Captura.PNG

Insulin Dosing for Fat and Protein:

Is it Time?

The impact of dietary fat and protein on postprandial glycemia in type 1 diabetes (T1D) and the need to adjust for them in the mealtime insulin dose have been controversial (1,2)...

Captura de Pantalla 2022-06-15 a la(s) 21.26_edited.png

Living Better with Life’s Simple 7TM

What if you had a guide ...

Captura de Pantalla 2022-06-15 a la(s) 21.31_edited.jpg

COMUNICADO DE GRETHA Y LA ALIANZA POR UN CORAZÓN SALUDABLE SOBRE LA RELACIÓN ENTRE COVID-19 Y EL USO DE MEDICAMENTOS QUE ACTUAN SOBRE EL SISTEMA RENINA-ANGIOTENSINA-ALDOSTERONA.

Como un grupo de expertos mexicanos en el manejo de la hipertensión arterial, reiteramos que el manejo epidemiológico de las pandemias como la que actualmente afecta a la humanidad, debe estar sujeto a protocolos estrictos, planeados y ejecutados por...

Captura de Pantalla 2022-06-15 a la(s) 21.49_edited.jpg

Standards for the development and methodology of the 2019 International Working Group on the Diabetic Foot guidelines

Diabetic foot disease is a source of major patient suffering and societal costs. Investing in evidence-based international guidelines on diabetic foot disease is likely among the most cost-effective forms of health care expenditure, provided the guide- lines are outcome focused, evidence based, and properly implemented.

Captura de Pantalla 2022-06-15 a la(s) 22.16_edited.png

Mechanism of glucose-lowering by metformin in type 2 diabetes: Role of bile acids

Type 2 diabetes mellitus (T2DM) is an increasingly prevalent chronic condition, char- acterized by abnormally elevated blood glucose concentrations and, as a conse- quence, increased risk of micro- and macrovascular complications.

Captura de Pantalla 2022-06-15 a la(s) 22.20_edited.jpg

Effects of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes in women versus men

Sodium-glucose co-transporter-2 (SGLT2) inhibitors prevent cardiovascular complica- tions in type 2 diabetes.

Captura de Pantalla 2022-06-15 a la(s) 22.25_edited.jpg

Empagliflozin Effectively Lowers Liver Fat Content in Well- Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial

Como un grupo de expertos mexicanos en el manejo de la hipertensión arterial, reiteramos que el manejo epidemiológico de las pandemias como la que actualmente afecta a la humanidad, debe estar sujeto a protocolos estrictos, planeados y ejecutados por...

Captura de Pantalla 2022-06-15 a la(s) 22.35_edited.jpg

Diabetes mellitus: a single cardiorenal syndrome umbrella

Diabetes and chronic kidney disease are among the fastest-growing causes of death worldwide. An optimized conceptual framework on the pathogenesis of diabetic kidney disease and its interplay with cardiovascular...

Captura de Pantalla 2022-06-15 a la(s) 22.44_edited.jpg

Glucagon-Like Peptide-1 Receptor Agonists in Adult Patients With Type 2 Diabetes: Review of Cardiovascular Outcome Trials

People with type 2 diabetes are at heightened risk for developing cardiovascular (CV) events. CV disease is the leading cause of premature death among adults with type 2 diabetes...

Captura de Pantalla 2022-06-15 a la(s) 22.50_edited.jpg

European Society of Endocrinology Clinical

Practice Guideline: Endocrine work-up in

obesity

R Pasquali1, F Casanueva2, M Haluzik3, L van Hulsteijn4, S Ledoux5, M P Monteiro6,7, J Salvador8,9, F Santini10, H Toplak11 and O M Dekkers...

Captura de Pantalla 2022-06-15 a la(s) 21.20_edited.jpg

Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study

Hiddo J L Heerspink, Avraham Karasik, Marcus Thuresson, Cheli Melzer-Cohen, Gabriel Chodick, Kamlesh Khunti, John P H Wilding, Luis Alberto Garcia Rodriguez, Lucia Cea-Soriano, Shun Kohsaka, Antonio Nicolucci, Giuseppe Lucisano, Fang-Ju Lin, Chih-Yuan Wang, Eric Wittbrodt, Peter Fenici, Mikhail Kosiborod

Captura de Pantalla 2022-06-15 a la(s) 21.28_edited.jpg

Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD

Andrew S. Levey, Ron T. Gansevoort, Josef Coresh, Lesley A. Inker, Hiddo L. Heerspink, Morgan E. Grams, Tom Greene, Hocine Tighiouart, Kunihiro Matsushita, Shoshana H. Ballew, Yingying Sang, Edward Vonesh, Jian Ying, Tom Manley, Dick de Zeeuw, Kai-Uwe Eckardt, Adeera Levin, Vlado Perkovic, Luxia Zhang, and Kerry Willis

Captura de Pantalla 2022-06-15 a la(s) 22.13_edited.png

Cardiovascular, renal and liver protection with novel antidiabetic agents beyond blood glucose lowering in type 2 diabetes

Vasilios Kotsisa, Jens Jordanb,c, Stella Staboulid, Christina Antzaa, Dragan Micice, Bojan Jelakovic ́f, Markus P. Schlaichg,h, Peter M. Nilssoni, Reinhold Kreutzj,k, Giuseppe Mancial, Kostas Tsioufism, and Guido Grassi

Captura de Pantalla 2022-06-15 a la(s) 22.11_edited.png

Optimal fasting glucose levels with regard to cardiovascular and mortality outcomes in people treated with or without antidiabetic medication

Aims: To investigate the optimal fasting blood glucose (FBG) levels among individuals actively treated or untreated with antidiabetic drugs.

Captura de Pantalla 2022-06-15 a la(s) 22.22_edited.jpg

Glucagon-like peptide-1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: An updated meta-analysis and subgroup analysis of randomized controlled trials

To evaluate whether the sodium–glucose cotransporter 2 inhibitor empagliflozin (EMPA) reduces liver fat content (LFC) in recent-onset and metabolically well- controlled type 2 diabetes (T2D).

Captura de Pantalla 2022-06-15 a la(s) 22.28_edited.png

Risk of Cardiovascular Events in Patients With Type

2 Diabetes and Metabolic Dyslipidemia Without

Prevalent Atherosclerotic Cardiovascular Disease

Division of Cardiology, Kaiser Permanente Northern California, Oakland, Calif; bDepartment of Medicine, University of California, San Francisco; cDivision of Research, Kaiser Permanente Northern California, Oakland, Calif; dHealth Economics and Outcomes Research, Medical Affairs, Regeneron Pharmaceuticals, Inc., Tarrytown, NY; eReal-World Evidence and Clinical Outcomes, Sanofi, Bridgewater, NJ.

Captura de Pantalla 2022-06-15 a la(s) 22.42_edited.png

Time to Rethink Reducing Cardiovascular Risk: Are We Ready?

The ultimate goal of managing diabetes is to improve quality of life and reduce diabetes-related complications—both microvascular and macrovascular.

Captura de Pantalla 2022-06-15 a la(s) 22.47_edited.jpg

Dietary Cholesterol and Cardiovascular Risk

The elimination of specific dietary cholesterol target recommendations in recent guidelines has raised questions about
its role with respect to cardiovascular disease...

Captura de Pantalla 2022-06-15 a la(s) 22.55_edited.png